Effectiveness of statin intensive therapy in type 2 diabetes mellitus with high visit-to-visit blood pressure variability.
Journal
Journal of hypertension
ISSN: 1473-5598
Titre abrégé: J Hypertens
Pays: Netherlands
ID NLM: 8306882
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
pubmed:
19
5
2021
medline:
16
10
2021
entrez:
18
5
2021
Statut:
ppublish
Résumé
Intensive lipid-lowering therapy is recommended in type 2 diabetes mellitus (T2DM) patients with target organ damage. However, the evidence is insufficient to stratify the patients who will benefit from the intensive therapy among them. High visit-to-visit variability in systolic blood pressure (SBP) is associated with increased risk of cardiovascular events. We investigated the effectiveness of intensive versus standard statin therapy in the primary prevention of cardiovascular events among T2DM patients with retinopathy stratified by visit-to-visit SBP variability. The standard versus intensive statin therapy for hypercholesterolemic patients with diabetic retinopathy study was the first trial comparing statin intensive therapy targeting low-density lipoprotein cholesterol (LDL-C) <70 mg/dl and standard therapy targeting LDL-C ≥100 to <120 mg/dl in T2DM patients with retinopathy without known cardiovascular disease. Using this dataset, we divided the patients into two subpopulations based on standard deviation (SD) and average real variability (ARV) of clinic SBP within the initial 6 months. In a total of 4899 patients, 240 composite cardiovascular events were observed during a median follow-up of 37.3 months. In multivariable-adjusted model comparing intensive versus standard therapy, the hazard ratios for composite cardiovascular events were 0.64 (95% CI 0.45-0.90) and 1.21 (95% CI 0.82-1.80) in patients with high and low SBP variability as defined by SD, respectively. Interaction between SBP variability and statin therapy was significant (P = 0.018). The analysis using ARV of SBP showed similar results. Statin intensive therapy targeting LDL-C <70 mg/dl had benefits in primary prevention of cardiovascular events compared with standard therapy among T2DM patients with retinopathy having high, but not low, visit-to-visit SBP variability.
Sections du résumé
BACKGROUND
Intensive lipid-lowering therapy is recommended in type 2 diabetes mellitus (T2DM) patients with target organ damage. However, the evidence is insufficient to stratify the patients who will benefit from the intensive therapy among them. High visit-to-visit variability in systolic blood pressure (SBP) is associated with increased risk of cardiovascular events. We investigated the effectiveness of intensive versus standard statin therapy in the primary prevention of cardiovascular events among T2DM patients with retinopathy stratified by visit-to-visit SBP variability.
METHODS
The standard versus intensive statin therapy for hypercholesterolemic patients with diabetic retinopathy study was the first trial comparing statin intensive therapy targeting low-density lipoprotein cholesterol (LDL-C) <70 mg/dl and standard therapy targeting LDL-C ≥100 to <120 mg/dl in T2DM patients with retinopathy without known cardiovascular disease. Using this dataset, we divided the patients into two subpopulations based on standard deviation (SD) and average real variability (ARV) of clinic SBP within the initial 6 months.
RESULTS
In a total of 4899 patients, 240 composite cardiovascular events were observed during a median follow-up of 37.3 months. In multivariable-adjusted model comparing intensive versus standard therapy, the hazard ratios for composite cardiovascular events were 0.64 (95% CI 0.45-0.90) and 1.21 (95% CI 0.82-1.80) in patients with high and low SBP variability as defined by SD, respectively. Interaction between SBP variability and statin therapy was significant (P = 0.018). The analysis using ARV of SBP showed similar results.
CONCLUSION
Statin intensive therapy targeting LDL-C <70 mg/dl had benefits in primary prevention of cardiovascular events compared with standard therapy among T2DM patients with retinopathy having high, but not low, visit-to-visit SBP variability.
Identifiants
pubmed: 34001809
doi: 10.1097/HJH.0000000000002823
pii: 00004872-202107000-00027
doi:
Substances chimiques
Cholesterol, LDL
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1435-1443Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685–696.
Knopp RH, D’Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care 2006; 29:1478–1485.
Itoh H, Komuro I, Takeuchi M, Akasaka T, Daida H, Egashira Y, et al. Intensive treat-to-target statin therapy in high-risk Japanese patients with hypercholesterolemia and diabetic retinopathy: report of a randomized study. Diabetes Care 2018; 41:1275–1284.
Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375:895–905.
Wan EYF, Yu EYT, Chin WY, Fong DYT, Choi EPH, Lam CLK. Association of visit-to-visit variability of systolic blood pressure with cardiovascular disease, chronic kidney disease and mortality in patients with hypertension. J Hypertens 2020; 38:943–953.
Vidal-Petiot E, Stebbins A, Chiswell K, Ardissino D, Aylward PE, Cannon CP, et al. Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. Eur Heart J 2017; 38:2813–2822.
Gosmanova EO, Mikkelsen MK, Molnar MZ, Lu JL, Yessayan LT, Kalantar-Zadeh K, et al. Association of systolic blood pressure variability with mortality, coronary heart disease, stroke, and renal disease. J Am Coll Cardiol 2016; 68:1375–1386.
Goldbourt U, Grossman E. Blood pressure variability at midlife is associated with all-cause, coronary heart disease and stroke long term mortality. J Hypertens 2020; 38:1722–1728.
Stevens SL, Wood S, Koshiaris C, Law K, Glasziou P, Stevens RJ, et al. Blood pressure variability and cardiovascular disease: systematic review and meta-analysis. BMJ 2016; 354:i4098.
Hata J, Arima H, Rothwell PM, Woodward M, Zoungas S, Anderson C, et al. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation 2013; 128:1325–1334.
Yu Z Bin, Li D, Chen XY, Zheng PW, Lin HB, Tang ML, et al. Association of visit-to-visit variability of blood pressure with cardiovascular disease among type 2 diabetes mellitus patients: a cohort study. Diabetes Metab J 2019; 43:350–367.
Radaelli MG, Ciardullo S, Perra S, Cannistraci R, Bianconi E, Muraca E, et al. Visit-to-visit blood pressure variability in patients with type 2 diabetes with and without previous history of cardiovascular disease. J Hypertens 2020; 38:1737–1744.
Newman JD, Schwartzbard AZ, Weintraub HS, Goldberg IJ, Berger JS. Primary prevention of cardiovascular disease in diabetes mellitus. J Am Coll Cardiol 2017; 70:883–893.
Brownrigg JRW, Hughes CO, Burleigh D, Karthikesalingam A, Patterson BO, Holt PJ, et al. Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol 2016; 4:588–597.
Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141:421–431.
Tadic M, Cuspidi C, Grassi G. Heart rate as a predictor of cardiovascular risk. Eur J Clin Invest 2018; 48:1–11.
Cardoso CRL, Leite NC, Salles GF. Prognostic importance of C-reactive protein in high cardiovascular risk patients with type 2 diabetes mellitus: the Rio de Janeiro type 2 diabetes cohort study. J Am Heart Assoc 2016; 5:e004554DOI: 10.1161/jaha.116.004554.
doi: 10.1161/jaha.116.004554
Kokubo Y. Associations of impaired glucose metabolism and dyslipidemia with cardiovascular diseases: what have we learned from Japanese cohort studies for individualized prevention and treatment? EPMA J 2011; 2:75–81.
Nishimura K, Okamura T, Watanabe M, Nakai M, Takegami M, Higashiyama A, et al. Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the Framingham risk score: the Suita study. J Atheroscler Thromb 2014; 21:784–798.
Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res 2017; 120:229–243.
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373:1175–1182.
Poortvliet RKE, Lloyd SM, Ford I, Sattar N, De Craen AJM, Wijsman LW, et al. Biological correlates of blood pressure variability in elderly at high risk of cardiovascular disease. Am J Hypertens 2015; 28:469–479.
Grassi G, Bombelli M, Brambilla G, Trevano FQ, Dell’oro R, Mancia G. Total cardiovascular risk, blood pressure variability and adrenergic overdrive in hypertension: evidence, mechanisms and clinical implications. Curr Hypertens Rep 2012; 14:333–338.
Kishi T. Heart failure as an autonomic nervous system dysfunction. J Cardiol 2012; 59:117–122.
Lewandowski J, Symonides B, Gaciong Z, Siński M. The effect of statins on sympathetic activity: a meta-analysis. Clin Auton Res 2015; 25:125–131.
Millar PJ, Floras JS. Statins and the autonomic nervous system. Clin Sci 2014; 126:401–415.
Quarti Trevano F, Seravalle G, Macchiarulo M, Villa P, Valena C, Dell’Oro R, et al. Reliability of heart rate as neuroadrenergic marker in the metabolic syndrome. J Hypertens 2017; 35:1685–1690.
Shiina K, Tomiyama H, Takata Y, Matsumoto C, Odaira M, Kato K, et al. Obstructive sleep apnea as possible causal factor for visit-to-visit blood pressure variability. Circ J 2016; 80:1787–1794.
Mason RP, Walter MF, Jacob RF. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation 2004; 109:I34–41.
Diaz KM, Veerabhadrappa P, Kashem MA, Feairheller DL, Sturgeon KM, Williamson ST, et al. Relationship of visit-to-visit and ambulatory blood pressure variability to vascular function in African Americans. Hypertens Res 2012; 35:55–61.
Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B, et al. Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9:469–480.
Smith TR, Drozda JP, Vanslette JA, Hoeffken AS, Nicholson RA. Medication class effects on visit-to-visit variability of blood pressure measurements: analysis of electronic health record data in the ‘real world’. J Clin Hypertens 2013; 15:655–662.
Mehlum MH, Liestøl K, Kjeldsen SE, Wyller TB, Julius S, Rothwell PM, et al. Blood pressure-lowering profiles and clinical effects of angiotensin receptor blockers versus calcium channel blockers. Hypertension 2020; 75:1584–1592.
Vishram JKK, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, et al. Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy. J Hypertens 2015; 33:2422–2430.
Kim JS, Park S, Yan P, Jeffers BW, Cerezo C. Effect of inter-individual blood pressure variability on the progression of atherosclerosis in carotid and coronary arteries: a post hoc analysis of the NORMALISE and PREVENT studies. Eur Heart Journal Cardiovasc Pharmacother 2017; 3:82–89.
Nwabuo CC, Yano Y, Moreira HT, Appiah D, Vasconcellos HD, Aghaji QN, et al. Long-term blood pressure variability in young adulthood and coronary artery calcium and carotid intima-media thickness in midlife: the CARDIA Study. Hypertension 2020; 76:404–409.
Ramos R, Comas-Cufí M, Martí-Lluch R, Balló E, Ponjoan A, Alves-Cabratosa L, et al. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. BMJ 2018; 362:k3359DOI: 10.1136/bmj.k3359.
doi: 10.1136/bmj.k3359
Parati G, Torlasco C, Pengo M, Bilo G, Ochoa JE. Blood pressure variability: its relevance for cardiovascular homeostasis and cardiovascular diseases. Hypertens Res 2020; 43:609–620.
Muntner P, Shimbo D, Diaz KM, Newman J, Sloan RP, Schwartz JE. Low correlation between visit-to-visit variability and 24-h variability of blood pressure. Hypertens Res 2013; 36:940–946.
Kario K. Prognosis in relation to blood pressure variability: pro side of the argument. Hypertension 2015; 65:1163–1169.
Sogunuru GP, Kario K, Shin J, Chen CH, Buranakitjaroen P, Chia YC, et al. Morning surge in blood pressure and blood pressure variability in Asia: evidence and statement from the HOPE Asia Network. J Clin Hypertens 2019; 21:324–334.
Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Pinar J, et al. Beneft of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Effcacy International Trial). Circulation 2018; 137:1571–1582.
Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol 2017; 5:941–950.